Abstract
Introduction: To assess gender-specific differences in recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) among patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC) receiving BCG was the primary aim of this systematic review and meta-analysis. Methods: In July 2023, we performed a literature search using MEDLINE, Embase, and the Cochrane Library. This study was prospectively registered at PROSPERO (CRD 2023443269). The detailed review protocol is accessible via CRD. Results: The systematic literature search identified 6,723 studies, of which 38 fulfilled the inclusion criteria. Random-effect meta-analysis for RFS, based on data from 24 studies, revealed no statistically significant gender-specific difference (HR comparing males to females = 0.9618, 95% CI: 0.8408–1.1003, p = 0.5707). Similarly, for PFS, incorporating data from 14 studies, no statistically significant difference (HR = 0.9540, 95% CI: 0.7709–1.1805, p = 0.6648), for CSS, analysis of data from three studies yielded no statistically significant difference (HR = 0.9228, 95% CI: 0.6196–1.3743, p = 0.6925), and for OS, based on data from two studies, no statistically significant difference was observed (HR = 1.1436, 95% CI: 0.5092–2.5684, p = 0.7452). The risk of bias assessment indicated an overall moderate to high risk of bias. Conclusion: The findings indicate no association between gender and oncologic outcomes following BCG.
Journal Section:
Research Article
References
1.
Bray
F
, Ferlay
J
, Soerjomataram
I
, Siegel
RL
, Torre
LA
, Jemal
A
. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
. CA Cancer J Clin
. 2018
;68
(6
):394
–424
. 2.
European Association of Urology (EAU) guidelines on muscle-invasive and metastatic bladder cancer
; 2023
. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-And-Metastatic-Bladder-Cancer-2022.pdf (Access 15. January 2024).3.
Bilski
K
, Kozikowski
M
, Skrzypczyk
MA
, Dobruch
A
, Hendricksen
K
, D’Andrea
D
, et al. Sex remains negative prognostic factor in contemporary cohort of high-risk non-muscle-invasive bladder cancer
. Cancers
. 2022
;14
(24
):6110
. 4.
European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer
. 2023
. Available from: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer (Access 15 January 2024).5.
Fadel
J
, Simonvan
D
, Fradet
V
, Lodde
M
, Lacombe
L
, Fradet
Y
, et al. Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer
. Urol Oncol
. 2022
;40
:539.e1
–e8
. 6.
Cochrane Germany
. Institut für Medizinische Biometrie und Statistik, Freiburg, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften- Institut für Medizinisches Wissensmanagement, Ärztliches Zentrum für Qualität in der Medizin. Manual zur Bewertung des Biasrisikos in Interventionsstudien
. 2 edn. Cochrane Germany
; 2021
. Available from: https://www.cochrane.de/de/literaturbewertung7.
Shu
D
, Young
JG
, Toh
S
, Wang
R
. Variance estimation in inverse probability weighted Cox models
. Biometrics
. 2021
;77
(3
):1101
–17
. 8.
9.
Ajili
F
, Darouiche
A
, Chebil
M
, Boubaker
S
. The efficacy of intravesical bacillus calmette-guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer
. Ultrastruct Pathol
. 2013
;37
(4
):278
–83
. 10.
Andius
P
, Holmang
S
. Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression
. BJU Int
. 2004
;93
(7
):980
–4
. 11.
Barry
E
, Agalliu
I
, Maiman
R
, Shreck
E
, Kovac
E
, Aboumohamed
A
, et al. Outcomes of intravesical bacillus calmette-guerin in a multiracial cohort with nonmuscle invasive bladder cancer
. Urol Pract
. 2021
;8
(1
):100
–5
. 12.
Birkhauser
F
, Rentsch
CA
, Studer
UE
, Albert
M
. 962 the BCG strain used is relevant for recurrence-free survival: a randomized phase III study comparing Immucyst® versus Oncotice®
. Eur Urol supplements
. 2012
;11
(1
):e962
–2a
. 13.
Boorjian
SA
, Zhu
F
, Herr
HW
. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder
. BJU Int
. 2010
;106
(3
):357
–61
. 14.
Bree
KK
, Hensley
PJ
, Brooks
N
, Matulay
J
, Nogueras-Gonzalez
GM
, Navai
N
, et al. Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center
. World J Urol
. 2021
;39
(11
):4143
–9
. 15.
Chen
YK
, Huang
EY
, Chang
YH
, Kuo
JY
, Chung
HJ
, Wu
HHH
, et al. The comparison of different BCG strains in the intravesical treatment of non-muscle invasive urothelial carcinoma of urinary bladder-a real-world practice
. J Chin Med Assoc
. 2022
;85
(9
):928
–34
. 16.
D’Andrea
D
, Soria
F
, Abufaraj
M
, Pones
M
, Gontero
P
, Machado
AT
, et al. Comparative effectiveness of intravesical BCG-tice and BCG-moreau in patients with non-muscle-invasive bladder cancer
. Clin Genitourin Cancer
. 2020
;18
(1
):20
–5.e2
. 17.
D’Andrea
D
, Soria
F
, Grotenhuis
AJ
, Cha
EK
, Malats
N
, Di Stasi
S
, et al. Association of patients’ sex with treatment outcomes after intravesical bacillus Calmette-Guérin immunotherapy for T1G3/HG bladder cancer
. World J Urol
. 2021
;39
(9
):3337
–44
. 18.
Decobert
M
, LaRue
H
, Harel
F
, Meyer
F
, Fradet
Y
, Lacombe
L
. Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough
. Cancer
. 2008
;113
(4
):710
–6
. 19.
Gontero
P
, Sylvester
R
, Pisano
F
, Joniau
S
, Vander Eeckt
K
, Serretta
V
, et al. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients
. Eur Urol
. 2015
;67
(1
):74
–82
. 20.
Herr
HW
. Age and outcome of superficial bladder cancer treated with bacille calmette-guerin therapy
. Urology
. 2007
;70
(1
):65
–8
. 21.
Herr
HW
, Badalament
RA
, Amato
DA
, Laudone
VP
, Fair
WR
, Whitmore
WF
Jr. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression
. J Urol
. 1989
;141
(1
):22
–9
. 22.
Hurle
R
, Buffi
N
, Lista
G
, Cardone
P
, Forni
G
, Maffei
D
, et al. Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center
. Minerva Urol Nefrol
. 2018
;70
(5
):501
–8
. 23.
Iida
K
, Naiki
T
, Kawai
N
, Etani
T
, Ando
R
, Ikegami
Y
, et al. Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer
. BMC Urol
. 2016
;16
(8
):8
. 24.
Irie
A
, Uchida
T
, Yamashita
H
, Matsumoto
K
, Satoh
T
, Koh
H
, et al. Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guerin for superficial bladder cancer recurrence
. Int J Urol
. 2003
;10
(4
):183
–9
. 25.
Kakiashvili
DM
, van Rhijn
BW
, Trottier
G
, Jewett
MAS
, Fleshner
NE
, Finelli
A
, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment
. BJU Int
. 2011
;107
(4
):540
–6
. 26.
Kamat
MR
, Kulkarni
JN
, Tongaonkar
HB
, Dalal
AV
. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain
. J Urol
. 1994
;152
(5 Pt 1
):1424
–8
. 27.
Kikuchi
H
, Abe
T
, Matsumoto
R
, Osawa
T
, Maruyama
S
, Murai
S
, et al. Outcomes of bacillus Calmette-Guerin therapy without a maintenance schedule for high-risk non-muscle-invasive bladder cancer in the second transurethral resection era
. Int J Urol
. 2022
;29
(3
):251
–8
. 28.
Kim
SJ
, Nam
W
, You
D
, Jeong
IG
, Song
C
, Hong
B
, et al. Prognostic factors related to recurrence-free survival for primary carcinoma in situ of the bladder after Bacillus calmette-guérin: a retrospective study
. Urol Int
. 2018
;101
(3
):269
–76
. 29.
Koguchi
D
, Matsumoto
K
, Hirayama
T
, Moroo
S
, Kobayashi
M
, Katsumata
H
, et al. Impact of maintenance therapy using a half dose of the bacillus Calmette-Guerin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study
. BMC Urol
. 2020
;20
(1
):194
. 30.
Krajewski
W
, Rodriguez Faba
O
, Breda
A
, Pisano
F
, Poletajew
S
, Tukiendorf
A
, et al. Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer
. World J Urol
. 2020
;38
(12
):3177
–82
. 31.
Liu
K
, Zhao
H
, Chen
X
, Ka-Fung Chiu
P
, Ng
CF
, Yuen-Chun Teoh
J
. MP08-17 bacillus calmette–guérin strains don’t matter: results from a territory-wide retrospective cohort study
. J Urol
. 2023
;209
(Suppl 4
):e101
. 32.
Milosevic
R
, Milovic
N
, Aleksic
P
, Lazic
M
, Cerovic
S
, Bancevic
V
, et al. S122: the influence of gender and age on the incidence of recurrence and disease progression in patients with muscle-non-invasive bladder cancer, depending on the optimal application of intravesical immunotherapy of bacillus Calmette-Guérin
. Eur Urol
. 2014
;13
(7
):e1486
. 33.
Miyamoto
T
, Miyake
M
, Toyoshima
Y
, Fujii
T
, Shimada
K
, Nishimura
N
, et al. Clinical outcomes after intravesical bacillus Calmette-Guérin for the highest-risk non-muscle-invasive bladder cancer newly defined in the Japanese Urological Association Guidelines 2019
. Int J Urol
. 2021
;28
(7
):720
–6
. 34.
Montesino-Semper
M
, Madero-Jarabo
R
, Solsona-Narbon
E
, Fernández-Gómez
J
, Alonso-Dorrego
J
, Chantada-Abal
V
, et al. Treatment of carcinoma in situ of the bladder associated or not associated to non-muscle invasive transitional carcinoma using two different bcg doses: the standard or one-third dose a five year follow-up
. Eur Urol
. 2010
;9
(2
):91
. 35.
Muto
S
, Nakajima
A
, Horiuchi
A
, Inoue
M
, China
T
, Saito
K
, et al. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer
. Jpn J Clin Oncol
. 2013
;43
(3
):305
–13
. 36.
Nurminen
P
, Nummi
A
, Kesti
O
, Ettala
O
, Högerman
M
, Järvinen
R
, et al. Comparison of Bacillus calmette-guerin maintenance therapy with monthly instillations and the southwest oncology group protocol in the treatment of non-muscle-invasive bladder cancer
. Eur Urol Focus
. 2023
;9
(6
):1000
–7
. 37.
Okamura
T
, Akita
H
, Ando
R
, Ikegami
Y
, Naiki
T
, Kawai
N
, et al. Single monthly bacillus Calmette-Guerin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer
. Int J Clin Oncol
. 2012
;17
(5
):477
–81
. 38.
Palou
J
, Sylvester
RJ
, Faba
OR
, Parada
R
, Peña
JA
, Algaba
F
, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin
. Eur Urol
. 2012
;62
(1
):118
–25
. 39.
Shakhssalim
N
, Dadpour
M
, Sharifiaghdas
F
, Narouie
B
, Askarpour Kabir
S
, Sepehran
E
, et al. Evaluating the effectiveness of intravesical instillation of BCG by modified maintenance method in patients with high-risk Ta and T1 bladder cancer: a randomized clinical trial
. Clin Med Insights Oncol
. 2023
;17
:11795549231184682
. 40.
Shinka
T
, Matsumoto
M
, Ogura
H
, Hirano
A
, Ohkawa
T
. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up
. Int J Urol
. 1997
;4
(2
):139
–43
. 41.
Takashi
M
, Wakai
K
, Hattori
T
, Furuhashi
K
, Ono
Y
, Ohshima
S
, et al. Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guerin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ
. Int Urol Nephrol
. 2002
;33
(1
):41
–7
. 42.
Tomida
R
, Miyake
M
, Minato
R
, Sawada
Y
, Matsumura
M
, Iida
K
, et al. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data
. Int J Clin Oncol
. 2022
;27
(5
):958
–68
. 43.
Williams
SB
, Howard
LE
, Foster
ML
, Klaassen
Z
, Sieluk
J
, De Hoedt
AM
, et al. Estimated costs and long-term outcomes of patients with high-risk non-muscle-invasive bladder cancer treated with Bacillus calmette-guérin in the veterans affairs Health system
. JAMA New Open
. 2021
;4
(3
):e213800
. 44.
Yoneyama
T
, Onyema
C
, Imai
A
, Ishimura
H
, Hagisawa
S
, Iwabuchi
I
, et al. Low-Dose instillation therapy with bacilli calmette-guerin Tokyo 172 strain after transurethral resection: historical cohort study
. Urology
. 2008
;71
:1161
–5
. 45.
Yuge
K
, Kikuchi
E
, Matsumoto
K
, Takeda
T
, Miyajima
A
, Oya
M
. Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy
. Jpn J Clin Oncol
. 2011
;41
(4
):565
–70
. 46.
Uhlig
A
, Strauss
A
, Hosseini
ASA
, Lotz
J
, Trojan
L
, Schmid
M
, et al. Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: a systematic review and meta-analysis
. Eur Urol Focus
. 2018
;6
:924
–36
. 47.
Hara
I
, Miyake
H
, Takechi
Y
, Eto
H
, Gotoh
A
, Fujisawa
M
, et al. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder
. Int J Urol
. 2003
;10
(1
):19
–24
. 48.
Jancke
G
, Damm
O
, Rosell
J
, Jahnson
S
. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer
. Scand J Urol Nephrol
. 2008
;42
(5
):417
–21
. 49.
McElree
IM
, Steinberg
RL
, Mott
SL
, O’Donnell
MA
, Packiam
VT
. Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus calmette-guérin for the treatment of patients with high-risk non-muscle-invasive bladder cancer
. JAMA Netw Open
. 2023
;6
(2
):e230849
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
